Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE

Summary

Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).

Timeline

Start

2022-07-12

Primary completion

2025-11-12

Completion

2025-11-12

Outcome

Outcome not reported

Stopped (Business): “This study was prematurely terminated due to sponsor decision.”

Drugs

Indications